ArticleBiometrics2009
Dose finding for continuous and ordinal outcomes with a monotone objective function: a unified approach.
Article in Biometrics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Bayesian model averaging for partial ordering continual reassessment methods.Biostatistics (Oxford, England) · 2025Article
- Evaluation of phase I clinical trial designs for combinational agents along with guidance based on simulation studies.Journal of applied statistics · 2023Review
- An adaptive gBOIN design with shrinkage boundaries for phase I dose-finding trials.BMC medical research methodology · 2021Article
- A Bayesian dose-finding design for outcomes evaluated with uncertainty.Clinical trials (London, England) · 2021Article
- Continual reassessment method with regularization in phase I clinical trials.Journal of biopharmaceutical statistics · 2020Article
- A surface-free design for phase I dual-agent combination trials.Statistical methods in medical research · 2020Article
- A flexible design for advanced Phase I/II clinical trials with continuous efficacy endpoints.Biometrical journal. Biometrische Zeitschrift · 2019Article
- Dose-finding designs for cumulative toxicities using multiple constraints.Biostatistics (Oxford, England) · 2019Article
- How to design a dose-finding study on combined agents: Choice of design and development of R functions.PloS one · 2019Article
- Sequential designs for individualized dosing in phase I cancer clinical trials.Contemporary clinical trials · 2017Article
- The rapid enrollment design for Phase I clinical trials.Statistics in medicine · 2016Article
- Practical designs for Phase I combination studies in oncology.Journal of biopharmaceutical statistics · 2016Review
- Advances in Statistical Approaches Oncology Drug Development.Therapeutic innovation & regulatory science · 2014Article
- Up-and-down designs for phase I clinical trials.Contemporary clinical trials · 2013Article
- Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicities.Statistics in medicine · 2013Article
- Adaptive Isotonic Estimation of the Minimum Effective and Peak Doses in the Presence of Covariates.Journal of statistical planning and inference · 2012Article
- Incorporating lower grade toxicity information into dose finding designs.Clinical trials (London, England) · 2011Article
- Continual reassessment method with multiple toxicity constraints.Biostatistics (Oxford, England) · 2011Article
- Risk-group-specific dose finding based on an average toxicity score.Biometrics · 2010Article
- Dose finding when the target dose is on a plateau of a dose-response curve: comparison of fully sequential designs.Pharmaceutical statisticsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
In many phase I trials, the design goal is to find the dose associated with a certain target toxicity rate. In some trials, the goal can be to find the dose with a certain weighted sum of rates of various toxicity grades. For others, the goal is to find the dose with a certain mean value of a continuous response. In this article, we describe a dose-finding design that can be used in any of the dose-finding trials described above, trials where the target dose is defined as the dose at which a certain monotone function of the dose is a prespecified value. At each step of the proposed design, the normalized difference between the current dose and the target is computed. If that difference is close to zero, the dose is repeated. Otherwise, the dose is increased or decreased, depending on the sign of the difference.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.